| Literature DB >> 22973172 |
Ebru Zemheri1, Seyma Ozkanli, Ilkin Zindanci, Serkan Senol, Ozge Akbulak, Elvan Turfanda, Mehtap Toprak, Duygu Kosemetin, Abdullah Aydin.
Abstract
BACKGROUND: There are not many studies investigating histomorphological changes in 48 sessions in patients with early-stage MF after narrowband UVB (NBUVB) treatment. Our purpose is to evaluate histological features of phototherapy after 48 sessions and determine which parameters are more reliable for controlling skin biopsies.Entities:
Mesh:
Year: 2012 PMID: 22973172 PMCID: PMC3438737 DOI: 10.1100/2012/426732
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Comparison of histopathological changes before and after the treatment.
| Before treatment | After treatment |
| |
|---|---|---|---|
|
|
| ||
| Epidermotropism | |||
| Single/haloed lymphocytes | 20 (62.5%) | 7 (21.9%) | 0.001** |
| Linearly arranged | 30 (93.8%) | 6 (18.8%) | 0.001** |
| lymphocytes | |||
| Pautrier microabscesses | 19 (59.4%) | 4 (12.5%) | 0.001** |
| Stratum corneum | |||
| Normal | 7 (21.9%) | 21 (65.6%) | 0.004** |
| Parakeratosis | 8 (25.0%) | 1 (3.1%) | 0.039* |
| Orthohyperkeratosis | 17 (53.1%) | 10 (31.3%) | 0.143 |
| Epidermis | |||
| Normal | 9 (28.1%) | 15 (46.9%) | 0.238 |
| Atrophic | 6 (18.8%) | 8 (25.0%) | 0.791 |
| Hyperplastic | 17 (53.1%) | 9 (28.1%) | 0.134 |
| Inflammatory infiltrates | |||
| Superficial, perivascular | — | 16 (50.0%) | 0.001** |
| Lichenoid/patchy lichenoid | 32 (100%) | 7 (21.9%) | 0.001** |
| No inflammation | — | 9 (28.1%) | 0.004** |
| Fibrosis | |||
| 0 | 6 (18.8%) | 6 (18.8%) | 1.000 |
| 1 | 22 (68.8%) | 22 (68.8%) | 1.000 |
| 2 | 3 (9.4%) | 3 (9.4%) | 1.000 |
| Other changes | |||
| Basal vacuolar degeneration | 1 (3.1%) | 7 (21.9%) | 0.070 |
| Dyskeratotic cells | 2 (6.3%) | 7 (21.9%) | 0.180 |
| Melanophages | 8 (25.0%) | 23 (71.9%) | 0.001** |
| Vascular changes | |||
| Telangiectasia | 7 (21.9%) | 14 (43.8%) | 0.118 |
| Vascular proliferation | 1 (3.1%) | 4 (12.5%) | 0.250 |
Mc Nemar test was used. *P< 0.05, **P< 0.01.
Figure 1Linearly arranged and single/haloed atypical lymphocytes in epidermis in patient with patch stage MF were seen before treatment (×400, H&E).
Figure 2Loss of linearly arranged cells, but persistence of single/haloed lymphocytes and Pautrier microabscess in the epidermis, fibrosis in the papillary dermis in nonresponder group after treatment were seen (×200, H&E).
Figure 3Basal vacuolar degeneration in epidermis and melanophages in papillary dermis were seen after treatment (×400, H&E).
Evaluation of parameters after the treatment, according to response to treatment.
| Response to treatment | |||
|---|---|---|---|
| After treatment | Yes | No |
|
|
|
| ||
| Epidermotropism | |||
| Single/haloed lymphocytes | 3 (13.0%) | 4 (44.4%) | 0.053 |
| Linearly arranged | 2 (8.7%) | 4 (44.4%) | 0.038* |
| lymphocytes | |||
| Pautrier microabscesses | 1 (4.3%) | 3 (33.3%) | 0.057 |
| Stratum corneum | |||
| Normal | 19 (82.6%) | 2 (22.2%) | 0.001** |
| Parakeratosis | 0 (0.0%) | 1 (11.1%) | 0.281 |
| Orthohyperkeratosis | 4 (17.4%) | 6 (66.7%) | 0.007** |
| Epidermis | |||
| Normal | 13 (56.5%) | 2 (22.2%) | 0.122 |
| Atrophic | 7 (30.4%) | 1 (11.1%) | 0.256 |
| Hyperplastic | 3 (13.0%) | 6 (66.7%) | 0.002** |
| Inflammatory infiltrates | |||
| Superficial. perivascular | 13 (52.1%) | 4 (44.4%) | 0.433 |
| Lichenoid/patchy lichenoid | 2 (8.7%) | 5 (55.6%) | 0.004** |
| No inflammation | 9 (39.1%) | 0 (0%) | 0.027* |
| Fibrosis | |||
| 0 | 6 (26.1%) | 0 (0.0%) | 0.150 |
| 1 | 15 (65.2%) | 7 (77.8%) | 0.491 |
| 2 | 1 (4.3%) | 2 (22.2%) | 0.184 |
| Other changes | |||
| Basal vacuolar degeneration | 7 (30.4%) | 0 (0.0%) | 0.061 |
| Dyskeratotic cells | 7 (30.4%) | 0 (0.0%) | 0.061 |
| Melanophages | 18 (78.3%) | 5 (55.6%) | 0.199 |
| Vascular changes | |||
| Telangiectasia | 10 (43.5%) | 4 (44.4%) | 0.960 |
| Vascular proliferation | 3 (13.0%) | 1 (11.1%) | 1.000 |
Chi-square and Fisher's Exact tests were used *P < 0.05, **P< 0.01.
Figure 4Lichenoid infiltration of atypical cell and fibrosis were seen in nonresponder group after treatment (×200, H&E).